Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 104Fallopian Tube Neoplasms 47Carcinoma, Ovarian Epithelial 27Neoplasms 12Breast Neoplasms 7Neoplasm Metastasis 5Recurrence 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Ovarian Cancer Recurrent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Multiple Myeloma 2Lung Neoplasms 2Disease Progression 2Colorectal Neoplasms 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sezary Syndrome 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1

Interventions

olaparib 1liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasm Epithelial × liposomal doxorubicin × Gynecologic × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡